Background We conducted a systematic review and meta-analysis to assess the effects of statin therapy on serum vitamin D concentrations.
Introduction
Statins are a class of lipid-lowering agents that inhibit the enzyme hydroxyl-methyl coenzyme A (HMG-CoA) reductase, a rate limiting enzyme in the synthesis of cholesterol [1, 2] . They are very effective agents in both primary and secondary prevention of cardiovascular diseases [3] [4] [5] [6] . Accordingly, statins are now widely used for those indications, with nearly a quarter of the USA adults currently taking a statin, while another 12Á8 million could be considered for therapy based on the latest guidelines [7] [8] [9] . Although it has been suggested that statins are relatively safe for prolonged use, there are still concerns that long-term commitment of individuals to statin could lead to the expression of some deleterious consequences of statins through a cumulative effect over time. There has been a suggestion for instance that statin use impairs vitamin D status, which in turn can increase the risk of different types of cancers and chronic disorders, including cardiovascular diseases [10, 11] . The major carrier of vitamin D in the blood is LDL-cholesterol, and hence, a reduction in LDL-cholesterol from statin use would tend to reduce the vitamin D being carried in this lipoprotein fraction. However, another mechanism has also been proposed based on the fact that both 25(OH) vitamin D and statins are metabolized in liver by a common enzyme of the cytochrome P450 system called CYP3A4 [12] . Occupation of the active site of this enzyme by statins may lead to an increase in serum 25(OH) vitamin D levels. Moreover, rosuvastatin and atorvastatin, but not fluvastatin, have been reported to increase circulating concentrations of 25(OH) D [13, 14] . However, existing studies diverge on possible effects of statins on Vitamin D status, and there has been no effort to systematically assess and characterize such effects. Moreover, existing studies to date have been limited by their sample size, research design and subject traits (gender, ethnicity, age, etc.) and underpowered to provide a comprehensive and reliable conclusion. Meta-analysis has the benefit of overcoming these limitations by increasing the sample size. Hence, considering the importance of vitamin D for human's health and disease risk, this study aimed to resolve uncertainties surrounding the association between statin use and vitamin D status, by systematically reviewing the literature, and pooling effects from randomized control trials investigating the effects of statin administration on vitamin D status.
Methods

Literature search strategy
We conducted a systematic review according to the international referred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines [15, 16] , using a protocol registered in the International Prospective Register of Systematic Reviews, PROSPERO (registration no: CRD42016035974). The exposure of interest was statin use, and the primary outcome was the change in vitamin D status subsequent to statin use. We searched multiple databases including PUBMED/ MEDLINE, Cochrane Central Register of Controlled Trials (CCTR), Cochrane Database of Systematic Reviews (CDSR), Web of Science, Googol Scholar and clinicaltrial.gov registry until May 2016, for published and unpublished studies on changes in vitamin D status in relation with statins use, using a combination of relevant search terms (Table S1 ). The wild-card term '*' was used to increase the sensitivity of the search strategy. No language restriction was applied. Additionally, we hand-searched the reference list of eligible articles and contacted authors for missing information/clarifications where relevant. The full text of studies meeting inclusion criteria was retrieved and screened to determine their eligibility by two reviewers (MM, PR). Disagreements were resolved through discussions between reviewers until consensus reached. Our study was in line with PRISMA statement along with references to PRISMA statement and the broader EQUATOR guidelines [17] .
Selection criteria
Eligible studies had to meet following criteria: (i) being a prospectively conducted study (clinical trial of parallel, crossover or single-arm design and observational studies with casecontrol, cross-sectional or cohort design) of patients treated with statins compared to a control group (either no statin or placebo), (ii) reporting on the effect of statin therapy on vitamin D concentrations, (iii) presentation of sufficient information on vitamin D concentrations at baseline and at the end of study in each group or providing the mean change during follow-up (for RCT papers). Exclusion criteria were as follows: (i) studies that did not provide mean (or median) plasma concentrations of vitamin D at baseline and/or at the end of trial and (ii) narrative reviews, comments, opinion pieces, methodological, editorials, conference abstract, letters or any other publications lacking primary data and/or explicit method descriptions were also excluded. After removal of duplicates, two investigators (MM & PR) independently screened title, abstract and full text of studies to determine appropriateness for inclusion. The agreement between the two investigators was excellent (Kappa index: 0Á86; P < 0Á001). Disagreements were resolved at a meeting between reviewers prior to selected articles being retrieved (a flow chart is available in the Fig. 1 ).
Data extraction and management
Two reviewers extracted data onto a purpose-designed data extraction form and independently summarized what they considered to be the most important results from each study. These summaries were compared, and any opinion differences were resolved by discussion and consultation with a third reviewer. Any further calculations on study data deemed necessary were conducted by the first reviewer and checked by the second reviewer. Data extracted included the first author's name, year, country, design, inclusion criteria, age range, total sample size, gender, dose (mg) and type of statins, and followup duration in weeks.
Quality assessment
A systematic assessment of bias in the RCTs was performed using the Cochrane criteria [18] . The items used for the assessment of each study were as follows: adequacy of random sequence generation, allocation concealment, blinding of participants, personnel and outcome assessment, handling of drop-outs (incomplete outcome data), selective outcome reporting and other potential sources of bias. According to the recommendations of the Cochrane Handbook, a judgment of 'yes' indicated low risk of bias, while 'no' indicated high risk of bias. Labelling an item as 'unclear' indicated an unclear or unknown risk of bias. For the rest of the papers [13, 14, 19, 20] , we assessed the methodological quality of included studies in terms of internal validity, external validity, response rate and generalizability of study results. We used the ten-item rating system developed by Hoy et al. [21] and modified by Werfalli et al. [22] to assess sampling, the sampling frame and size, outcome measurement, outcome assessment, response rate and statistical reporting [21] . Each item was assigned a score of 1 (yes) or Zero (no), and scores were summed across items to generate an overall quality score that ranged from 0 to 10. Each study was rated as having a low, moderate or high risk of bias depending on the number of questions answered as 'yes (low risk)': studies at low risk of bias had scores higher than 8, moderate a score of 6-8 and high a score of 5 or lower. Risk of selection and attrition biases were assessed according to the Cochrane guidelines, in REVIEW MANAGER, version 5.2 (Nordic Cochrane Centre, Cochrane Collaboration, Dale, AL, USA). Two reviewers (MM and PR) independently assessed study quality, with disagreements being resolved by consensus.
Data synthesis
When the outcome measure was reported as median and range [or 95% confidence interval (CI)], mean and standard deviation (SD) values were estimated using the method described by Hozo et al. [23] . Plasma vitamin D (25[OH]D) levels were collated in ng/mL. Where vitamin D levels were reported in nM, they were converted to ng/mL by dividing by 2Á5. Where standard error of the mean (SEM) was only reported, the SD was estimated using the following formula: SD ¼ SEM Â ffiffiffi n p , where n is the sample size [24] . When relevant data were available only in graphical form, the software GETDATA GRAPH DIGITIZER 2.24 [25] was applied to digitize and extract the data. Random-effects models meta-analysis was then used to pool estimates across studies [26] . Heterogeneity was quantitatively assessed using I 2 index. Effect sizes were expressed as weighed mean difference (WMD) and 95% CI. To evaluate the influence of each study on the overall effect size, sensitivity analysis was conducted using the leave-one-out method, that is removing one study each time and repeating the analysis [24, [27] [28] [29] .
Publication bias
The presence of publication bias was explored via visual inspection of Begg's funnel plot asymmetry, Begg's rank correlation and Egger's weighted regression tests [24] . Duval & Tweedie 'trim-and-fill' and 'fail-safe N' methods were then used to adjust the analysis for the effects of publication bias [30] . This meta-analysis used the COMPREHENSIVE META-ANALYSIS (CMA) V3 software (Biostat, NJ, USA) [31] .
Results
Characteristics of the included studies
The summary of searches and study selection process is summarized in Fig. 1 . Table 1 presents the key characteristics of the studies included in the review. Four of these were prospective cohort studies, and three were randomized controlled trials, all published from 2006 to 2016. These studies were conducted in six countries including Turkey (two studies), Iran, Hong Kong, UK, Denmark and Spain (one study each). The number of participants per study ranged from 37 [32] to 134 [13] ; and inclusion criteria varied across studies. Two studies enrolled only female participants, while the proportion of women across the remaining studies ranged from 25% [19] to 68% [13] . The mean age of participants ranged from 26Á6 years [32] to 68 years [19] . The duration of follow-up across RCTs and cohort studies ranged from 8 weeks [2] to 65 weeks [13] . The statin of interest was rosuvastatin in two studies [13, 14] , simvastatin in two studies [2, 33] , atorvastatin in two studies Table 1 [ 20, 32] .
Risk of bias assessment
Two of the included studies were characterized by lack of information about the allocation concealment, selective reporting and blinding of participants and personnel; however, almost all evaluated studies had a low risk of bias according to selective outcome reporting. Details of the quality of bias assessment are shown in Table S2 . Moreover, details of quality assessment for cohort studies are illustrated in Table S3 .
Estimates of the effects of statin therapy on vitamin D concentrations in individual studies
In studies using rosuvastatin, two reported significant effects on vitamin D concentration [13, 14] . In studies using simvastatin, one reported significant effects on vitamin D concentration [2] . In studies using atorvastatin, two reported significant effects on vitamin D concentration [20, 32] .
Pooled estimate of the effect of statin therapy on vitamin D concentrations
The pooled estimate (weighted mean difference) of the effect of statin therapy on serum vitamin D from RCT studies was 2Á71 ng/mL (95% CI 0Á19-5Á24, I 2 62Á1%) (Fig. 2) . However, a meta-analysis of the remaining studies indicated a significant decrease in vitamin D concentration subsequent to statins therapy: À0Á70 ng/mL (95% CI À1Á20 to À0Á20, I 2 56Á3%) (Fig. 3) .
Sensitivity analysis
In leave-one-out sensitivity analyses, the pooled effect estimates remained similar for both RCTs and non-RCTs: 2Á71 ng/mL (95% CI 0Á19-5Á24) and À0Á70 ng/mL (95% CI À1Á20 to À0Á20), respectively. This stability confirms that the significant difference between the studied groups is the overall effect of all included studies.
Publication bias
Visual inspection of funnel plot asymmetry suggested potential publication bias (Fig. 4) . However, the presence of publication bias was not suggested by Egger's linear regression (intercept = 6Á40, standard error = 2Á95; 95% CI À2Á99 to 15Á79, t = 2Á16, df = 3, P = 0Á113,) while Begg's rank correlation test (Kendall's Tau with continuity correction = 1Á00, z = 2Á44, P = 0Á014) was indicative of publication bias. After adjustment of the effect size for potential publication bias using the 'trimand-fill' correction, three potentially missing studies were imputed in funnel plot, which changed the estimated effect size to WMD 0Á18 ng/mL (95% CI À2Á19 to 2Á57) (Fig. 5) . The 'failsafe N' test showed that 84 studies would be needed to bring the WMD down to a nonsignificant P-value (P ≥ 0Á05).
Discussion
The meta-analysis of selected data in the present study showed that there was a significant reduction in serum vitamin D following treatment with statins. Previous investigations on the impact of statin therapy on circulating vitamin D levels have showed contradictory results. Although atorvastatin [20] , rosuvastatin [14, 34] and simvastatin [35] vitamin D and some statins are metabolized in the liver by a common enzyme of the cytochrome P450 system that is called CYP3A4 [12] . CYP3A4 is recognized as the main enzyme involved in the metabolism of drugs in the liver; hence, potential interactions between promising new drugs and CYP3A4 are assessed starting at the early stages of their development [36] [37] [38] . Statins can be classified as lipophilic or hydrophilic [39] . Atorvastatin, simvastatin, lovastatin, fluvastatin and pitavastatin are lipophilic and undergo first-pass metabolism by gut and liver [39, 40] . Atorvastatin is highly lipophilic with low oral bioavailability (5-10%) [40] . Pravastatin and rosuvastatin are hydrophilic statins with good oral bioavailability. Not all statins are metabolized in a similar way [39, 41] . Three of the statins are metabolized primarily by CYP3A4: simvastatin, atorvastatin and lovastatin; fluvastatin is metabolized by CYP2C9, while pravastatin and rosuvastatin are not significantly metabolized by CYP enzymes [40] . Pitavastatin is marginally metabolized by CYP2C9 and to a lesser extent by CYP2C8 [40, 41] . As vitamin D is an inducer of CYP3A4 and CYP2C9, it can be expected that it will help in the metabolism of certain statins and reduce their toxic side effects [40] . The fact that vitamin D is a known inducer of CYP3A4 and the metabolites are responsible for pharmacologic activity explains the enhanced enzyme activity and reduced toxicity of atorvastatin after vitamin D supplementation [42] . CYP3A4 metabolites of lovastatin and simvastatin are inactive. As inhibition of CYP3A4 metabolism results in increased toxicity [42] , enhancing CYP3A4 metabolism should result in fast metabolism and less drug availability for muscle toxicity. Therefore, occupation of the active site of this enzyme by statins may account for an increased serum 25(OH) vitamin D levels. Another possibility proposed by authors from Greece is that when 3-hydroxy-3 methylglutaryl coenzyme A reductase is inhibited by statins, 7-hydrocholesterol levels (the common precursor of cholesterol and 25(OH) vitamin D) may increase, thereby providing an abundance of substrate for the synthesis of 25(OH) vitamin D by ultraviolet sun radiation of the skin; in fact, this mechanism is the case for more tropical area of world [34] .
Some limitations should be noted. The majority of the included studies had relatively small sample sizes, potentially leading to overestimation of treatment effects, because smaller trials might be methodologically less robust and are prone to report larger effect sizes [43, 44] . The number of available studies on the described topic was rather small, although some studies published in grey literature could have been missed in searches. Furthermore, the dose of supplied vitamin D in the analysed studies and the duration of the supplementation were different and could influence the full interpretation of the collected data.
Conclusion
This meta-analysis was inconclusive on the effects of statins on vitamin D, with conflicting directions of the effects from interventional and observational studies. The suggested favourable effects from RCTs need to be confirmed in larger studies with extended follow-up in order to determine the possible health benefits.
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